- 92Bio revives a T cell engager it had transferred to AmgenA small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After repeatedly saying it would bring the drug…Endpoints · 27d ago↗ source
- Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data🩻 Angitia Biopharmaceuticals drops Phase 3: The US and China biotech terminated a late-stage trial of AGA111 in patients with degenerative disc disease who had a lumbar interbody fusion, according…Endpoints · 27d ago↗ source
- 5 FDA decisions to watch in the third quarter of 2026A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.BioPharma Dive